It's crunch time: Tips to make up for lost dollars
The year 2005 will portend a significant decrease in income for nearly every American urologist. Most will be impacted by Medicare's slashing the reimbursement for LHRH agonists and certain other drugs administered in the office. Solo practitioners can anticipate annual losses of income in the thousands of dollars, and larger group practices can expect over a $1 million shortfall this year.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.